The expertise and commitment of our R&D and management teams and the fruitful collaboration with independent or academic research institutes and recognized contract research organizations brought Neurim Pharmaceuticals remarkable successes in drug discovery and development. Neurim Pharmaceuticals has one product registrated, several Phase II/III projects to develop new indications and further 19 internally developed NCEs at various stages of preclinical and clinical development. All products of Neurim Pharmaceuticals are based on small molecule chemical synthesis.

The following indications are being developed:

1. Primary Insomnia, primarily in elderly
2. Non-24-hour sleep-wake disorder
3. Chronic Insomnia
   

The following NCE's are in development:

1. Parkinson's Disease
2. Asthma/COPD
3. Psychophysiological Insomnia